Zachary A Cutshall (Zachary Cutshall)

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Health Insurance

Metastatic Renal Cell Carcinoma

Metal Organic Framework

Top Venues

JCO oncology practice

Foot & ankle international

This page only lists publications with an associated author ORCID identifier.

Publications

Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Patrick J Kellam, Zachary A Cutshall, Graham J DeKeyser, David L Rothberg, Thomas F Higgins, Justin M Haller, Lucas S Marchand
Recovery Curve for Patients With Pilon Fractures Using Patient-Reported Outcome Measurement Information System. Foot & ankle international (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice (2023)
Minkyoung Yoo, Richard E Nelson, Zachary A Cutshall, Maura Dougherty, Manish Kohli
Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective. JCO oncology practice 19 (3) (2023)